Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coronavirus - Botswana: No vaccine manufacturing company has withdrawn from an agreement with Botswana for supply of COVID-19 vaccines

07/30/2021 | 10:29am EDT

The Ministry of Health and Wellness has noted with concern a story in the Sunday Standard/The Telegraph social media platform indicating that Moderna has withdrawn from its agreement to supply COVID-19 vaccine doses to Botswana. In the said article, the paper states that Moderna withdrew from the sale agreement after the Ministry of Health and Wellness had failed to pay the vaccine company.

The ministry wishes to state for a fact that it's agreement with Moderna for the supply of 500 000 doses, still stands. The two have a legally binding agreement that remains in force. The ministry further states that it has not reneged on making any payments to the company. Instead, the ministry has paid a total of USD 4, 332, 000 as part payment for the 500 000 doses procured. Payment of the balance is currently being processed. As stated by the Minister of Health and Wellness Hon. Dr Edwin G. Dikoloti in Parliament this morning, the ministry expects delivery of Moderna doses from August 2021.

The ministry therefore, advises the Sunday Standard/The Telegraph newspaper to desist from misinforming members of the public about a matter so sensitive and dear to their lives, as COVID-19 vaccines. Such misinformation can potentially lead to unnecessary panic, confusion, anxiety and hopelessness, especially at a time when many are looking up to the Government to do all it can to bring home COVID-19 vaccines. Media houses should therefore, follow all known news reporting principles of verifying facts before publishing and giving each party an opportunity to respond to matters that concern them. This did not happen in this case.

The ministry wishes to assure members of the public that it still expects the arrival of vaccines in August 2021, including Moderna, as was so elaborately declared by Minister Dr Dikoloti in Parliament this morning. In the event that there are any changes, the ministry will communicate as it always does with any developments in the COVID-19 pandemic.

Distributed by APO Group on behalf of Ministry of Health and Wellness, Republic of Botswana.


(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about MODERNA, INC.
05:26pMODERNA : U.S. CDC Says 212,564,346 Individuals Have Received At Least One Dose Of Covid-1..
12:12pMODERNA : EU drugs regulator to decide on Pfizer vaccine booster in early October
12:01pGLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
11:06aASTRAZENECA : Vaccination Against Covid-19 Resumes Sept 24
05:51aMODERNA : EU regulator to decide on Pfizer booster at the start of October - source
04:41aMODERNA : COVID-19 Pandemic Could Be Over Within One Year, Moderna CEO Says
03:49aModerna chief executive sees pandemic over in a year - newspaper
02:21aASTRAZENECA : invests in Imperial's self-amplifying RNA technology with eye on future drug..
01:29aMODERNA : REFILE-Moderna chief executive sees pandemic over in a year - newspaper
09/22ASTRAZENECA : Japan doubles COVID-19 vaccine donation pledge to 60 mln doses
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 15,3x
Yield 2021 -
Capitalization 183 B 183 B -
EV / Sales 2021 8,38x
EV / Sales 2022 7,78x
Nbr of Employees 1 300
Free-Float 90,3%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 16
Last Close Price 454,60 $
Average target price 306,23 $
Spread / Average Target -32,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.335.15%177 895
LONZA GROUP AG33.16%61 006
CELLTRION, INC.-20.75%31 824
SEAGEN INC.-3.41%30 776